Will Trevi Therapeutics (TRVI) Take Off After Dismal 2019?

(RTTNews) - Trevi Therapeutics Inc. (TRVI), whose share performance was dismal in 2019, has some important catalysts to watch out for this year.

The Company is developing Nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.

Nalbuphine ER is an oral, extended-release formulation of Nalbuphine. Administered as a subcutaneous injection for relief of moderate to severe pain in the hospital setting, Nalbuphine was approved by the FDA in 1979.

The ongoing clinical trials with Nalbuphine ER include:

-- A phase 2b/3 trial in approximately 240 patients with severe pruritus from prurigo nodularis in approximately 50 centers in the U.S. and Europe, dubbed PRISM, is ongoing. A sample size re-estimation analysis once 50% of the patients in the trial are evaluable for the primary endpoint is slated for mid-2020.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2020    »